SCHEMBL2882238

SCHEMBL2882238

Cc1ccccc1C1CCN(C(=O)O)CC1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 2/20 0.43
KCNH2 Q12809 1/20 0.42
HSD11B1 P28845 1/20 0.42
BRD4 O60885 1/20 0.41
TRPV1 Q8NER1 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTR2B P41595 1/20 0.39
MAPK14 Q16539 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAOB P27338 1/20 0.39
SLC6A9 P48067 1/20 0.38
SLC6A5 Q9Y345 1/20 0.38
HTT P42858 2/20 0.38
NPC1 O15118 2/20 0.38
TP53 P04637 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 1/20 0.38
NFKB1 P19838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2883527 1.00 OPRL1 (0.43) OPRL1KCNH2HSD11B1BRD4TRPV1
SCHEMBL2882613 0.84 HSD11B1 (0.41) HSD11B1BRD4TRPV1CYP2C9CYP2C19
SCHEMBL2882609 0.84 HSD11B1 (0.41) HSD11B1BRD4TRPV1CYP2C9CYP2C19
SCHEMBL2882780 0.84 HSD11B1 (0.41) HSD11B1BRD4TRPV1CYP2C9CYP2C19
SCHEMBL2882782 0.83 RAB9A (0.47) HSD11B1CYP2C9CYP2C19HTR2BMAPK14
SCHEMBL2883668 0.82 HSD11B1 (0.40) HSD11B1BRD4TRPV1CYP2C9CYP2C19
SCHEMBL2882007 0.81 SMN1; SMN2 (0.54) CYP2C9CYP2C19HTTNPC1RAB9A
SCHEMBL6041552 0.81 HRH3 (0.43) CYP2C9CYP2C19ALDH1A1
SCHEMBL2241229 0.80 SLC18A3 (0.55) ALDH1A1HTTNPC1TP53RAB9A
SCHEMBL2241225 0.80 SLC18A3 (0.55) ALDH1A1HTTNPC1TP53RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855294-B2 Cycloalkanopyridine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-21 US disclosed
US-20070191419-A1 Cycloalkanopyridine derivative MSD K.K. (JP) 2007-08-16 US disclosed
EP-1726590-A1 CYCLOALKANOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191419-A1 Cycloalkanopyridine derivative OPRL1, OPRK1, AVPR2 OPRL1 1/4885KCNH2 969/4885HSD11B1 1480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.